Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CETP | P11597 | 3/20 | 1.00 |
| ▸ | UBE2N | P61088 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Safingol SCHEMBL5061324 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| Dihydrospingosine SCHEMBL12563458 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| Safingol SCHEMBL6772 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1131930 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL16455713 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL12330738 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1131985 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL21660227 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL21431064 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL18127645 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190117590-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | TEXAS TECH UNIVERSITY SYSTEM | 2019-04-25 | — | — | US | disclosed |
| EP-2669267-B1 | Compositions and methods for treating hyperproliferative disorders | TEXAS TECH UNIV (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9763980-B2 | Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-09-19 | — | — | US | disclosed |
| US-20140193376-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2669267-A1 | Compositions and methods for treating hyperproliferative disorders | TEXAS TECH UNIVERSITY (US) | 2013-12-04 | — | — | EP | disclosed |
| US-20130217691-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | TEXAS TECH UNIVERSITY SYSTEM (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2501672-A2 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS | TEXAS TECH UNIVERSITY (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20110152267-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | TEXAS TECH UNIVERSITY SYSTEM | 2011-06-23 | — | — | US | disclosed |
| WO-2011060332-A2 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS | TEXAS TECH UNIVERSITY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117590-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | SGMS1, S1PR1, SPHK1 | CYP2D6 4551/4885SPHK1 3/4885LMNA 1618/4885 |
| US-20140193376-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | S1PR1, S1PR4, S1PR3 | CYP2D6 4600/4885SPHK1 7/4885LMNA 3889/4885 |
| US-20110152267-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | SGMS1, S1PR1, SPHK1 | CYP2D6 4551/4885SPHK1 3/4885LMNA 1618/4885 |
| US-20130217691-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | SGMS1, S1PR1, SPHK1 | CYP2D6 4551/4885SPHK1 3/4885LMNA 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.